In the case of tyrosine kinase inhibitors utilized to target the BCR::ABL1 fusion product in CML [117], mature leukemic cells are effectively eliminated, but quiescent CML stem cells selectively survive [118, 119, 120]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.